资源类型

期刊论文 145

年份

2023 12

2022 13

2021 11

2020 10

2019 13

2018 6

2017 8

2016 7

2015 10

2014 9

2013 3

2012 9

2011 2

2010 5

2009 13

2008 4

2007 3

2000 1

1999 1

展开 ︾

关键词

医院中子照射器 3

硼中子俘获治疗 3

硼中子俘获疗法 3

靶向药物 2

2型糖尿病 1

ADAM10抑制剂 1

BNCT 1

BPA 1

FLT3抑制剂 1

G蛋白偶联受体 1

Logistic分析 1

SARS-CoV-2 1

cDNA克隆 1

三维适形放疗 1

中子俘获疗法 1

中药，类风湿关节炎，循证治疗，展望 1

临床试治 1

临床试验 1

人与机器人交互；机器人提升疗法；社会交互式机器人；机器人介导干预 1

展开 ︾

检索范围：

排序： 展示方式：

How to judge the association of postmenopausal hormone therapy and the risk of breast cancer

Ling XU

《医学前沿（英文）》 2010年 第4卷 第3期   页码 290-293 doi: 10.1007/s11684-010-0093-7

摘要： The relevance of postmenopausal hormone therapy (HT) for breast cancer risk has been long debated, although it is one of the most important barriers for women to accept HT. Various opinions have been reported from recent randomized clinical trials and epidemiological studies. These unanswered questions include: whether HT has a positive impact on breast cancer; whether risks of therapy with unopposed estrogen and combined estrogen-progestin are different; and whether different types and routes of estrogen and progestogens, as well as the duration and cessation of HT use, have different impacts on this disorder. Recently, there has been some good news such as the following: the currently available data do not provide sufficient evidence to prove a causal relationship between postmenopausal HT and breast cancer; breast cancer in postmenopausal women using HT usually has better prognosis than that of nonusers. In conclusion, HT is still the most effective method of relieving climacteric symptoms for many postmenopausal women. However, a possible risk of breast cancer associated with long-term HT usage should not be ignored. With respect to prevention of breast cancer, regular evaluation of individual breast cancer susceptibility and close follow-up through mammography and/or breast sonography are necessary strategies for the safety of HT use.

关键词： breast cancer     postmenopausal hormone therapy     unopposed estrogen therapy     combined estrogen-progestin therapy    

HTML PDF 收藏

Effects of exercise therapy on bone mineral density in early postmenopausal women: a controlled trial

Shilin DENG MD ,

《医学前沿（英文）》 2009年 第3卷 第3期   页码 323-329 doi: 10.1007/s11684-009-0061-2

摘要： The purpose of this article is to determine the effect of a well-designed combined aerobic, resistance, and extension exercise program on bone mineral density (BMD) in postmenopausal women. The population comprised 45 postmenopausal women, who exercised over 12months (exercise group), and 36 women who served as a non-training control group. BMD of the hip, and lumbar spine was measured at the baseline and 12th month. Repeated measurement analysis of variance and nonparametric test were utilized to compare differences between the exercise group and controls. Thirty-six out of 45 persons in the exercise group and 36 controls completed the study. Average compliance was 82.2% for the whole exercise group at the 12th month. All the subjects had decreased BMD, but the rate of bone loss was lower in the exercise group than in the control group at the L4 and hip. Although the exercise program in this study may probably reduce the rate of bone loss in weight-bearing skeletal sites, we do not suggest the exercise by itself be viewed as prevention or treatment for osteoporosis. Further, the exact dose-response relationship of exercise and bone mass in early postmenopause is not clear.

关键词： early postmenopausal women     bone mineral density     exercise     effects    

HTML PDF 收藏

Sensitivity of supplementation of thyroid hormone on treatment of idiopathic short-stature children duringtherapy with recombinant human growth hormone

Wei Wang, Shuqin Jiang, Zhirui Cui, Xiangyang Luo, Lingli Shi, Heli Zheng

《医学前沿（英文）》 2018年 第12卷 第5期   页码 580-585 doi: 10.1007/s11684-017-0585-9

摘要：

This study aimed to evaluate the effects of thyroid hormone supplementation on growth rate of children with idiopathic short stature (ISS) and low-normal serum free thyroxine FT4 who were receiving growth hormone therapy. We selected 64 prepubertal children with FT4 levels in the lowest third of the normal range as the lower FT4 group, and these children were divided randomly into two subgroups: L-thyroxine (L-T4)-treated subgroup was treated with L-T4 (0.5–3.0 g/(kg·d)) from the beginning of the study, and the non-L-T4-treated subgroup received placebo. We also selected 39 ISS children with FT4 in the upper two-thirds of the normal range as the higher FT4 group. During the first year, the lower FT4 group featured lower FT3, FT4, thyroid stimulating hormone (TSH), and insulin-like growth factor-I standard deviation score (IGF-I SDS) and significantly lower height velocity (HV) compared with the higher FT4 group. However, in the lower FT4 group, the L-T4-treated subgroup presented higher FT4, FT3, TSH, and IGF-I SDS concentrations and significantly higher HV compared with children in the non-L-T4-treated subgroup. In children with ISS, the negative effect of thyroid hormone deficiency on growth rate should be considered when FT4 level lies in the low-normal range prior to recombinant human growth hormone treatment.

关键词： therapeutic     idiopathic short-stature children     free T4     the first year     recombinant human growth hormone    

HTML PDF 收藏

Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor

Wenjie Zhu, Binghe Xu

《医学前沿（英文）》 2021年 第15卷 第2期   页码 208-220 doi: 10.1007/s11684-020-0795-4

摘要： New targeted therapies have been developed to overcome resistance to endocrine therapy (ET) and improve the outcome of HR /HER2 advanced breast cancer (ABC). We conducted a meta-analysis and systemic review on randomized controlled trials evaluating various targeted therapies in combination with ET in HR /HER2 ABC. PUBMED and EMBASE databases were searched for eligible trials. Hazard ratios (HRs) for progression-free survival (PFS), odds ratios (ORs) for objective response rate (ORR), clinical benefit rate (CBR), and toxicity were meta-analyzed. Twenty-six studies with data on 10 347 patients were included and pooled. The addition of cyclin-dependent kinase 4/6 inhibitors to ET significantly improved median PFS (pooled HR= 0.547, <0.001), overall survival (pooled HR= 0.755, <0.001), and tumor response rates (ORR, pooled OR= 1.478, <0.001; CBR, pooled OR= 1.201, <0.001) with manageable toxicities (pooled OR= 3.280, <0.001). The mammalian targets of rapamycin inhibitors and exemestane were not clinically beneficial for this pooled population including ET-naïve and ET-resistant patients. Moderate improvement in PFS (pooled HR= 0.686, <0.001) yet pronounced toxicities (pooled OR= 2.154, <0.001) were noted in the combination of phosphatidylinositol-4,5-bisphosphate 3-kinase inhibitors with fulvestrant. Future studies are warranted to optimize the population and the dosing sequence of these available options.

关键词： endocrine-resistant     HR+/HER2- advanced breast cancer     randomized clinical trials     meta-analysis     targeted therapy    

HTML PDF 收藏

Atypical pituitary hormone–target tissue axis

《医学前沿（英文）》 2023年 第17卷 第1期   页码 1-17 doi: 10.1007/s11684-022-0973-7

摘要： A long-held belief is that pituitary hormones bind to their cognate receptors in classical target glands to actuate their manifold functions. However, a number of studies have shown that multiple types of pituitary hormone receptors are widely expressed in non-classical target organs. Each pituitary gland-derived hormone exhibits a wide range of nonconventional biological effects in these non-classical target organs. Herein, the extra biological functions of pituitary hormones, thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone, adrenocorticotrophic hormone, and prolactin when they act on non-classical organs were summarized, defined by the novel concept of an “atypical pituitary hormone–target tissue axis.” This novel proposal explains the pathomechanisms of abnormal glucose and lipid metabolism, obesity, hypertension, fatty liver, and atherosclerosis while offering a more comprehensive and systematic insights into the coordinated regulation of environmental factors, genetic factors, and neuroendocrine hormones on human biological functions. The continued exploration of the physiology of the “atypical pituitary hormone–target tissue axis” could enable the identification of novel therapeutic targets for metabolic diseases.

关键词： thyroid-stimulating hormone     follicle-stimulating hormone     luteinizing hormone     adrenocorticotrophic hormone     prolactin    

HTML PDF 收藏

Clinical evaluation of recombinant human growth hormone injection in children with growth hormone deficiency

Ling HOU, Xiaoping LUO, Minlian DU, Huamei MA, Chunxiu GONG, Yuchuan LI, Shuixian SHEN, Zhuhui ZHAO, Li LIANG, Guanping DONG, Chaoying YAN, Hongwei DU

《医学前沿（英文）》 2009年 第3卷 第2期   页码 171-176 doi: 10.1007/s11684-009-0027-4

摘要： Recombinant human growth hormone (rhGH) has been widely used in the clinical treatment of growth hormone deficiency. To simplify the injection process and increase drug compliance, application of the GH injection has become a new treatment plan in recent years. The purpose of the current study was to evaluate the efficacy and safety of rhGH injection for the treatment of growth hormone deficiency (GHD) in children in China. In a nationwide, noncomparative, prospective, randomized, open trial, 31 children with confirmed complete GHD received subcutaneous injection of rhGH at 0.25 mg/kg·wk (0.107 IU/kg·d). The injection was given daily and the total weekly amount was separated into 6-7 injections. The patients were followed up at 3-month intervals and the treatment duration was 12 months. The height (HT), annual growth velocity (GV), mean height standard deviation score (HT SDS), blood serum insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and bone maturity before and after treatment were compared, and the safety of the treatment was analyzed. The mean HT, GV, and HT SDS were increased from 109.0±14 cm, 2.7±0.9 cm/yr, and -4.62±1.46 at baseline to 121.8±13.4 cm, 12.9±3.3 cm/yr, and -2.47±1.86 after 12 months of treatment, respectively ( <0.001). At the same time, blood IGF-I and IGFBP-3 were increased significantly [41.27±64.43 μg/L 159.21±167.92 μg/L and 1540.00±1325.11 mg/L 3533.93±1413.82 mg/L, respectively ( <0.001)]. The bone age assessments performed 6 and 12 months after the treatment showed that no advanced bone maturation was noted. No serious adverse events occurred during the treatment, and the drug-related adverse events were mainly decreased thyroid function. We conclude that rhGH injection is a safe and effective drug for treatment of growth hormone deficiency in children.

关键词： recombinant human growth hormone     injection     growth hormone deficiency    

HTML PDF 收藏

复方口服避孕药对垂体-卵巢轴激素及卵泡发育的影响

黄培,黄勋彬

《中国工程科学》 2015年 第17卷 第6期   页码 16-20

摘要： 但在周期性的COCs的无活性药间期（hormone-free interval， HFI）会有垂体-卵巢轴活性的恢复，其激素水平的变化及卵泡发育的情况与雌激素的剂量、孕激素的剂型、HFI的改变相关。

关键词： 复方口服避孕药     无活性药间期     激素     卵泡    

HTML PDF 收藏

农村绝经后妇女性生活满意度及其影响因素分析

景秀,杨继高,刘俊,张丽华

《中国工程科学》 2014年 第16卷 第5期   页码 105-109

摘要：

为了探索影响农村绝经后妇女性生活满意度的因素，从而为开展老年妇女保健提供科学依据，笔者于2012 年3—8 月采用多阶段随机抽样方法对重庆市5 个区县农村绝经后妇女采用统一方法进行问卷调查和体检。结果显示，重庆市农村绝经后妇女对目前性生活满意和不满意的分别占83.7 %和16.3 %。单因素分析显示，绝经后妇女性生活满意度与其婚姻状况、文化程度、家庭收入、家庭结构、是否患有妇科疾病、最近两周是否有生殖道不适、起居方式、是否需要性生活、性生活频率、老年性保健知识、自觉体力状态及自觉生活状态等12 个变量有关（P<0.05）；多因素Logistic 回归分析显示，分居方式（比值比（OR）=1.711，95 %置信区间（CI）为1.334～2.194）、性生活频率高（OR=1.694，95 % CI 为1.334～2.152）、自觉体力状态差（OR=1.281，95 % CI 为1.018～1.613）是危险因素，家庭收入高（OR=0.651，95 % CI 为0.512～0.826）和既往有妇科疾病（OR=0.689，95 % CI 为0.486～0.977）是保护因素。因此，农村存在多种影响绝经后妇女性生活满意度的相关因素，应重视对绝经后妇女的性教育，改善她们的生活质量。

关键词： 绝经后妇女     性生活满意度     影响因素     Logistic分析    

HTML PDF 收藏

RECENT ADVANCES IN THE REGULATION OF CLIMACTERIC FRUIT RIPENING: HORMONE, TRANSCRIPTION FACTOR AND EPIGENETIC

《农业科学与工程前沿（英文）》 2021年 第8卷 第2期

摘要：

Fruit ripening is a complex developmental process made up of genetically programmed physiological and biochemical activities. It culminates in desirable changes in the structural and textural properties and is governed by a complex regulatory network. Much is known about ethylene, one of the most important metabolites promoting the ripening of climacteric fruits. However, the dynamic interplay between phytohormones also plays an important part. Additional regulatory factors such as transcription factors (TFs) and epigenetic modifications also play vital role in the regulation of climacteric fruit ripening. Here, we review and evaluate the complex regulatory network comprising interactions between hormones and the action of TFs and epigenetic modifications during climacteric fruit ripening.

 

关键词： climacteric fruit ripening / phytohormones / TFs / epigenetic modifications    

HTML PDF 收藏

RECENT ADVANCES IN THE REGULATION OF CLIMACTERIC FRUIT RIPENING: HORMONE, TRANSCRIPTION FACTOR AND EPIGENETIC

Yinglin JI, Mingyang XU, Aide WANG

《农业科学与工程前沿（英文）》   页码 314-334 doi: 10.15302/J-FASE-2021386

摘要： Fruit ripening is a complex developmental process made up of genetically programmed physiological and biochemical activities. It culminates in desirable changes in the structural and textural properties and is governed by a complex regulatory network. Much is known about ethylene, one of the most important metabolites promoting the ripening of climacteric fruits. However, the dynamic interplay between phytohormones also plays an important part. Additional regulatory factors such as transcription factors (TFs) and epigenetic modifications also play vital role in the regulation of climacteric fruit ripening. Here, we review and evaluate the complex regulatory network comprising interactions between hormones and the action of TFs and epigenetic modifications during climacteric fruit ripening.

关键词： climacteric fruit ripening     phytohormones     TFs     epigenetic modifications    

HTML PDF 收藏

美洲鲥鱼卵巢发育规律和性类固醇激素变化研究

洪磊,李兆新,陈超,郭正龙,王蔚芳,雷霁霖

《中国工程科学》 2014年 第16卷 第9期   页码 86-92

摘要：

采用组织学、形态学及电化学等技术方法，研究了人工养殖条件下美洲鲥鱼雌性亲鱼卵巢发育和性类固醇激素的周期变化规律。结果表明，美洲鲥鱼属于非同步分批产卵类型；根据卵巢外部形状大小及色泽等的不同，可将美洲鲥鱼卵巢发育过程分为6 个时期；根据卵母细胞的形态结构、卵黄物质的积累和滤泡细胞的变化，将卵子发生划分为6 个时相；卵巢周期变化过程中，肝脏指数（HSI）和肥满度（CF）变化不显著，性腺指数（GSI）与血浆中雌二醇（E2）水平表现出与性腺发育协同一致的变化规律。

关键词： 美洲鲥鱼     卵巢发育     卵子发生     组织学     形态学     性类固醇激素    

HTML PDF 收藏

Particle therapy for cancers: a new weapon in radiation therapy

null

《医学前沿（英文）》 2012年 第6卷 第2期   页码 165-172 doi: 10.1007/s11684-012-0196-4

摘要：

Particle irradiation started to draw attention in the past decade and has now become a hotspot in the radiation oncology community. This article reviews the most advanced developments in particle irradiation, focusing on the characteristics of proton and carbon ions in radiation physics and radiobiology. The Bragg peak of physical dose distribution causes proton and carbon beams to optimally meet the requirement for cancer irradiation because the Bragg peak permits the accurate concentration of the dose on the tumor, thus sparing the adjacent normal tissues. Moreover, carbon ion has more radiobiological benefits than photon and proton beams. These benefits include stronger sterilization effects on intrinsic radio-resistant tumors and more effective killing of hypoxic, G0, and S phase cells. Compared with the most advanced radiation techniques using photon, such as three-dimensional conformal radiation therapy and intensity-modulated radiation therapy, proton therapy has yielded more promising outcomes in local control and survival for head and neck cancers, prostate carcinoma, and pediatric cancers. Carbon therapy in Japan showed even more promising results than proton therapy. The local controls and overall survivals were as good as that treated by surgery in early stages of non-small cell lung cancer, hepatocellular carcinoma, prostate carcinoma, and head and neck cancers, especially for such highly resistant tumors as melanoma. The non-invasive nature of particle therapy affords more patients with chances to receive and benefit from treatment. Particle therapy is gradually getting attention from the oncology community. However, the cost of particle therapy facilities has limited the worldwide use of this technology.

关键词： radiation therapy     particle therapy     proton     carbon     cancer    

HTML PDF 收藏

Passive antibody therapy in emerging infectious diseases

《医学前沿（英文）》 doi: 10.1007/s11684-023-1021-y

摘要： The epidemic of corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 and its variants of concern (VOCs) has been ongoing for over 3 years. Antibody therapies encompassing convalescent plasma, hyperimmunoglobulin, and neutralizing monoclonal antibodies (mAbs) applied in passive immunotherapy have yielded positive outcomes and played a crucial role in the early COVID-19 treatment. In this review, the development path, action mechanism, clinical research results, challenges, and safety profile associated with the use of COVID-19 convalescent plasma, hyperimmunoglobulin, and mAbs were summarized. In addition, the prospects of applying antibody therapy against VOCs was assessed, offering insights into the coping strategies for facing new infectious disease outbreaks.

关键词： SARS-CoV-2     COVID-19     convalescent plasma     hyperimmunoglobulin     neutralizing monoclonal antibodies    

HTML PDF 收藏

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Shi-Yong Sun

《医学前沿（英文）》 2021年 第15卷 第2期   页码 221-231 doi: 10.1007/s11684-020-0812-7

摘要： The mammalian target of rapamycin (mTOR) critically regulates several essential biological functions, such as cell growth, metabolism, survival, and immune response by forming two important complexes, namely, mTOR complex 1 (mTORC1) and complex 2 (mTORC2). mTOR signaling is often dysregulated in cancers and has been considered an attractive cancer therapeutic target. Great efforts have been made to develop efficacious mTOR inhibitors, particularly mTOR kinase inhibitors, which suppress mTORC1 and mTORC2; however, major success has not been achieved. With the strong scientific rationale, the intriguing question is why cancers are insensitive or not responsive to mTOR-targeted cancer therapy in clinics. Beyond early findings on induced activation of PI3K/Akt, MEK/ERK, and Mnk/eIF4E survival signaling pathways that compromise the efficacy of rapalog-based cancer therapy, recent findings on the essential role of GSK3 in mediating cancer cell response to mTOR inhibitors and mTORC1 inhibition-induced upregulation of PD-L1 in cancer cells may provide some explanations. These new findings may also offer us the opportunity to rationally utilize mTOR inhibitors in cancer therapy. Further elucidation of the biology of complicated mTOR networks may bring us the hope to develop effective therapeutic strategies with mTOR inhibitors against cancer.

关键词： mTOR     cancer therapy     resistance     GSK3     protein degradation     E3 ubiquitin ligase     PD-L1    

HTML PDF 收藏

Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects

Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao

《医学前沿（英文）》 2019年 第13卷 第4期   页码 427-437 doi: 10.1007/s11684-018-0672-6

摘要： Desmoid-type fibromatosis (DF) is a rare monoclonal fibroblastic proliferation that is characterized by locally infiltrative but rarely metastatic lesions. Tyrosine kinase and γ-secretase inhibitors are primarily used in the targeted therapy of DF. The use of these drugs, however, is mainly based on the recommendations of retrospective studies with small sample sizes. Previous studies that focused on the mechanism, efficacy, and safety of targeted therapy for DF were reviewed to provide references for clinical applications and research. The efficacy and safety of targeted therapy were compared with those of other systemic therapy options. Targeted therapy does not provide considerable advantages in efficacy and safety over other medical treatments and is usually applied after the failure of antihormonal therapies, nonsteroidal anti-inflammatory drugs, and chemotherapy. Further studies are required to explore the mechanism, indications, and appropriate drug dosage of the targeted therapy of DF.

关键词： targeted therapy     desmoid-type fibromatosis     tyrosine kinase inhibitor     γ-secretase inhibitor    

HTML PDF 收藏

标题 作者 时间 类型 操作

How to judge the association of postmenopausal hormone therapy and the risk of breast cancer

Ling XU

期刊论文

Effects of exercise therapy on bone mineral density in early postmenopausal women: a controlled trial

Shilin DENG MD ,

期刊论文

Sensitivity of supplementation of thyroid hormone on treatment of idiopathic short-stature children duringtherapy with recombinant human growth hormone

Wei Wang, Shuqin Jiang, Zhirui Cui, Xiangyang Luo, Lingli Shi, Heli Zheng

期刊论文

Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor

Wenjie Zhu, Binghe Xu

期刊论文

Atypical pituitary hormone–target tissue axis

期刊论文

Clinical evaluation of recombinant human growth hormone injection in children with growth hormone deficiency

Ling HOU, Xiaoping LUO, Minlian DU, Huamei MA, Chunxiu GONG, Yuchuan LI, Shuixian SHEN, Zhuhui ZHAO, Li LIANG, Guanping DONG, Chaoying YAN, Hongwei DU

期刊论文

复方口服避孕药对垂体-卵巢轴激素及卵泡发育的影响

黄培,黄勋彬

期刊论文

农村绝经后妇女性生活满意度及其影响因素分析

景秀,杨继高,刘俊,张丽华

期刊论文

RECENT ADVANCES IN THE REGULATION OF CLIMACTERIC FRUIT RIPENING: HORMONE, TRANSCRIPTION FACTOR AND EPIGENETIC

期刊论文

RECENT ADVANCES IN THE REGULATION OF CLIMACTERIC FRUIT RIPENING: HORMONE, TRANSCRIPTION FACTOR AND EPIGENETIC

Yinglin JI, Mingyang XU, Aide WANG

期刊论文

美洲鲥鱼卵巢发育规律和性类固醇激素变化研究

洪磊,李兆新,陈超,郭正龙,王蔚芳,雷霁霖

期刊论文

Particle therapy for cancers: a new weapon in radiation therapy

null

期刊论文

Passive antibody therapy in emerging infectious diseases

期刊论文

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Shi-Yong Sun

期刊论文

Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects

Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao

期刊论文